NeuroVive Pharmaceutical AB—amendment number of shares and votes
Pursuant to chapter 4, § 9 of the Swedish Financial Instruments Trading Act (1991:980), the company is hereby reporting that as a result of new share issues conducted by NeuroVive Pharmaceutical AB (publ) (“NeuroVive”), as resolved by an Extraordinary General Meeting (EGM) on 13 December 2013, and decided by the Board of Directors with the authorization of a shareholders’ meeting on 31 January 2014, the number of shares and votes of NeuroVive registered with the Swedish Companies Registration Office have increased by 6,129,047. Accordingly, the total number of shares and votes in NeuroVive is 27,788,093.
NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, is developing a portfolio of products to treat acute cardiovascular and neurological conditions through mitochondrial protection. These medical conditions are characterized by a pressing medical need and have no approved pharmaceutical treatment options at present. NeuroVive’s products CicloMulsion® (heart attack) and NeuroSTAT® (traumatic brain injury) are currently being evaluated in phase III and phase II studies, respectively. NeuroVive’s research programs also include products for the treatment of anti-viral indications (hepatitis B/C), brain cell injury in stroke patients, and drug candidates for cellular protection and treating mitochondria-related energy regulation diseases. NeuroVive’s shares are listed on NASDAQ OMX, Stockholm, Sweden.
For media and investor relations questions, please contact:
Ingmar Rentzhog, Laika Consulting, tel: +46 (0)46 275 62 21 or email@example.com
It is also possible to arrange an interview with NeuroVive’s CEO Mikael Brönnegård via the contact above.
NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: + 46 (0)46 888 83 48, firstname.lastname@example.org, www.neurovive.se
NeuroVive Pharmaceutical AB (publ) is required to publish the information in this news release under The Swedish Securities Market Act. The information was submitted for publication on 31 March 2014, at 8:30 a.m. CET.